Immune checkpoint inhibitors (ICI) have significantly improved melanoma-specific survival (MSS), particularly in patients with tumors with a high tumor mutational burden (TMB) or <i>BRAF</i> mutation. This evidence concerns the gene BRAF and neoplasm.